(ESTA) Establishment Labs Holdings - Overview
Stock: Breast Implants, Tissue Expanders
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 69.6% |
| Relative Tail Risk | -9.84% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.39 |
| Alpha | 84.17 |
| Character TTM | |
|---|---|
| Beta | 1.869 |
| Beta Downside | 2.080 |
| Drawdowns 3y | |
|---|---|
| Max DD | 71.43% |
| CAGR/Max DD | 0.01 |
Description: ESTA Establishment Labs Holdings January 19, 2026
Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a Costa-based medical-technology firm that designs, manufactures, and markets silicone gel-filled breast implants (Motiva) and breast tissue expanders for aesthetic and reconstructive plastic surgery. Its products are sold worldwide-through distributors and a direct sales force-to physicians, hospitals, and clinics across Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and North America. The company was incorporated in 2004 and remains headquartered in Alajuela, Costa Rica.
Key recent metrics: 2023 revenue reached approximately $150 million, reflecting a 12 % year-over-year increase driven by rising demand for premium-segment implants and expanded distribution in emerging markets. The global aesthetic surgery market is projected to grow at a 6-7 % CAGR through 2028, with breast augmentation accounting for roughly 30 % of procedure volume, providing a favorable tailwind for ESTA. However, the firm’s earnings are sensitive to foreign-exchange fluctuations (notably USD/CAD and EUR/USD) and to regulatory timelines for FDA clearance of new product lines, which introduces material uncertainty to forward forecasts.
For a deeper, data-driven perspective on ESTA’s valuation dynamics, consider exploring ValueRay’s analytical tools to supplement your research.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -83.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.23 > 0.02 and ΔFCF/TA -0.86 > 1.0 |
| NWC/Revenue: 87.77% < 20% (prev 86.53%; Δ 1.24% < -1%) |
| CFO/TA -0.21 > 3% & CFO -71.4m > Net Income -83.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (29.6m) vs 12m ago 6.15% < -2% |
| Gross Margin: 68.74% > 18% (prev 0.65%; Δ 6809 % > 0.5%) |
| Asset Turnover: 61.45% > 50% (prev 54.15%; Δ 7.30% > 0%) |
| Interest Coverage Ratio: -2.42 > 6 (EBITDA TTM -48.1m / Interest Expense TTM 24.0m) |
Altman Z'' -2.97
| A: 0.49 (Total Current Assets 239.6m - Total Current Liabilities 72.0m) / Total Assets 338.9m |
| B: -1.46 (Retained Earnings -493.1m / Total Assets 338.9m) |
| C: -0.19 (EBIT TTM -58.1m / Avg Total Assets 310.8m) |
| D: -0.20 (Book Value of Equity -65.6m / Total Liabilities 322.5m) |
| Altman-Z'' Score: -2.97 = D |
Beneish M -3.05
| DSRI: 0.85 (Receivables 71.4m/67.3m, Revenue 191.0m/153.1m) |
| GMI: 0.95 (GM 68.74% / 65.08%) |
| AQI: 1.00 (AQ_t 0.05 / AQ_t-1 0.05) |
| SGI: 1.25 (Revenue 191.0m / 153.1m) |
| TATA: -0.03 (NI -83.0m - CFO -71.4m) / TA 338.9m) |
| Beneish M-Score: -3.05 (Cap -4..+1) = AA |
What is the price of ESTA shares?
Over the past week, the price has changed by +9.45%, over one month by +3.50%, over three months by +49.06% and over the past year by +137.98%.
Is ESTA a buy, sell or hold?
- StrongBuy: 5
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ESTA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 83.3 | 16.8% |
| Analysts Target Price | 83.3 | 16.8% |
| ValueRay Target Price | 76.7 | 7.7% |
ESTA Fundamental Data Overview February 03, 2026
P/B = 122.8518
Revenue TTM = 191.0m USD
EBIT TTM = -58.1m USD
EBITDA TTM = -48.1m USD
Long Term Debt = 246.5m USD (from longTermDebt, last quarter)
Short Term Debt = 11.7m USD (from shortTermDebt, last quarter)
Debt = 261.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 190.5m USD (from netDebt column, last quarter)
Enterprise Value = 2.17b USD (1.98b + Debt 261.2m - CCE 70.6m)
Interest Coverage Ratio = -2.42 (Ebit TTM -58.1m / Interest Expense TTM 24.0m)
EV/FCF = -28.00x (Enterprise Value 2.17b / FCF TTM -77.5m)
FCF Yield = -3.57% (FCF TTM -77.5m / Enterprise Value 2.17b)
FCF Margin = -40.59% (FCF TTM -77.5m / Revenue TTM 191.0m)
Net Margin = -43.45% (Net Income TTM -83.0m / Revenue TTM 191.0m)
Gross Margin = 68.74% ((Revenue TTM 191.0m - Cost of Revenue TTM 59.7m) / Revenue TTM)
Gross Margin QoQ = 70.09% (prev 68.76%)
Tobins Q-Ratio = 6.41 (Enterprise Value 2.17b / Total Assets 338.9m)
Interest Expense / Debt = 2.38% (Interest Expense 6.20m / Debt 261.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -45.9m (EBIT -58.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.33 (Total Current Assets 239.6m / Total Current Liabilities 72.0m)
Debt / Equity = 15.96 (Debt 261.2m / totalStockholderEquity, last quarter 16.4m)
Debt / EBITDA = -3.96 (negative EBITDA) (Net Debt 190.5m / EBITDA -48.1m)
Debt / FCF = -2.46 (negative FCF - burning cash) (Net Debt 190.5m / FCF TTM -77.5m)
Total Stockholder Equity = 32.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.70% (Net Income -83.0m / Total Assets 338.9m)
RoE = -253.8% (Net Income TTM -83.0m / Total Stockholder Equity 32.7m)
RoCE = -20.81% (EBIT -58.1m / Capital Employed (Equity 32.7m + L.T.Debt 246.5m))
RoIC = -17.43% (negative operating profit) (NOPAT -45.9m / Invested Capital 263.3m)
WACC = 11.53% (E(1.98b)/V(2.24b) * Re(12.80%) + D(261.2m)/V(2.24b) * Rd(2.38%) * (1-Tc(0.21)))
Discount Rate = 12.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.61%
Fair Price DCF = unknown (Cash Flow -77.5m)
EPS Correlation: 30.67 | EPS CAGR: 4.49% | SUE: 1.00 | # QB: 1
Revenue Correlation: 47.46 | Revenue CAGR: 11.87% | SUE: 1.56 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.49 | Chg30d=-0.027 | Revisions Net=+2 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.94 | Chg30d=-0.072 | Revisions Net=-1 | Growth EPS=+49.2% | Growth Revenue=+24.6%